论文部分内容阅读
目的研究采用唑来膦酸治疗原发性骨质疏松症的临床疗效。方法 166例原发性骨质疏松症随机分为治疗组及对照组各83例,两组均给予口服钙尔奇D 600 mg,每日1次。治疗组给予唑来膦酸4 mg静脉注射,每年1次。结果 140例得到10~26个月随访,平均13.4个月,与对照组比较,治疗组骨痛症状评分明显下降(P<0.05);通过定量CT(QCT)检测腰椎骨密度,骨密度增加明显(P<0.05)。结论唑来膦酸治疗原发性骨质疏松症疗效显著,值得临床推广应用。
Objective To study the clinical efficacy of zoledronic acid in the treatment of primary osteoporosis. Methods 166 cases of primary osteoporosis were randomly divided into treatment group and control group of 83 cases, both groups were given oral calcium 600 mg, once daily. The treatment group given zoledronic acid 4 mg intravenously once a year. Results 140 cases were followed up for 10 to 26 months with an average of 13.4 months. Compared with the control group, the score of bone pain symptom in the treatment group decreased significantly (P <0.05). The BMD of the lumbar vertebra was significantly increased by quantitative CT (QCT) (P <0.05). Conclusion Zoledronic acid treatment of primary osteoporosis significant effect, worthy of clinical application.